ABSTRACT
P
eripheral neuropathies can be divided into mononeuropathies, polyneuropathies, and plexopathies. Patients present with pain, sensory symptoms, and/or motor deficits in the distribution of a single peripheral nerve, multiple peripheral nerves, or a nerve plexus. Mononeuropathies affect a single peripheral nerve. Polyneuropathies affect multiple peripheral nerves. In plexopathies, symptoms are localized to the brachial or lumbosacral plexus.
Polyneuropathies are generally attributable to systemic diseases (eg, diabetes and vitamin deficiencies), while mononeuropathies are most often due to trauma, nerve compression syndromes that occur at a few characteristic anatomic locations, or mass lesions. History and physical examination, supplemented in a subset of cases by laboratory studies, electrodiagnostic studies, and neuroimaging, are the main tools for diagnostic evaluation. In patients with a classic compression mononeuropathy, such as median nerve compression at the carpal tunnel, the diagnosis can often be made clinically and corroborated by needle electromyography, nerve conduction, and/or imaging studies. [1] [2] [3] [4] For mononeuropathies involving nerves not typically susceptible to compression syndromes, imaging can play an essential role in identifying the lesion and guiding management.
Plexopathies give rise to motor and/or sensory deficits in an extremity. Most brachial plexopathies (75%) are attributable to postradiation changes, primary and metastatic lung cancer, or metastatic breast cancer. 5 Common causes of lumbosacral plexopathy are primary and metastatic tumor, including cervical, endometrial, ovarian, prostate, testicular, and colorectal cancer; postradiation changes; and diabetes. 6 For patients with a history of radiation for malignancy, recurrent tumor with nerve invasion must be distinguished from radiation plexopathy; both can develop months to years following therapy and can have similar clinical presentations. 6 Although benign and malignant primary nerve sheath tumors, infiltration of nerves by metastatic disease, and postradiation neuritis require different therapeutic approaches, they also demonstrate overlapping features on MR imaging, including T2 hyperintensity, focal enlargement, and enhancement. 7, 8 Diffusivity measurements from DWI may be helpful in differentiating distinct pathologic entities. In prior studies, DWI was useful in differentiating malignant and benign peripheral nerve sheath tumors, 9 retroperitoneal masses, 10 head and neck tumors, 11, 12 and lymph nodes. 13, 14 Other studies have demonstrated differences in the diffusivities of adult 15 or pediatric brain tumors 16 that correlate with tumor grade and/or histologic type. In this study, we focus on masslike or infiltrative lesions of the peripheral nerves detected by MR imaging in patients presenting clinically with a peripheral mononeuropathy or plexopathy. We characterize and compare the diffusivities of these lesions and demonstrate significant differences among benign and malignant peripheral nerve tumors and postradiation changes.
MATERIALS AND METHODS

Study Population
Twenty-three patients referred for MR neurography at our institution between 2003 and 2009 by neurologists, neurosurgeons, and oncologists for a clinical indication of a peripheral mononeuropathy or brachial or lumbosacral plexopathy and who received a definitive diagnosis of a masslike or infiltrative nerve lesion based on biopsy results, long-term clinical and imaging follow-up, or intermediate-term follow-up supplemented by PET, neurologic examination, and/or nerve conduction studies were included in the study population. We included patients with noncystic "mass"-like lesions, defined as noncystic lesions with a diameter at least 50% larger than that of the apparent nerve of origin as well as patients with more infiltrative lesions consisting of more subtle nerve thickening and/or effacement of normally visualized interfascicular and surrounding fat planes without the presence of a well-defined "mass." Study participants were divided into 3 groups according to the final most likely pathologic diagnosis. Group 1 (n ϭ 10) consisted of benign lesions; Group 2 (n ϭ 7), malignant tumors; and Group 3 (n ϭ 6), postradiation changes, without evidence of residual tumor.
MR Neurography
MR imaging sequences performed at 1.5T (Gyroscan Intera 1.5T; Philips Healthcare, Best, the Netherlands) included axial and coronal STIR (TR ϭ 2200 ms, TE ϭ 20 ms, TI ϭ 160 ms, NEX ϭ 4, FOV ϭ 22, matrix ϭ 256 ϫ 192, slice thickness/gap ϭ 3/0.3 mm), T1 and fat-saturated postgadolinium T1-weighted spin-echo (TR ϭ 500, TE ϭ 14, NEX ϭ 3), and DWI (single-shot echoplanar imaging, 6 directions, TR ϭ 2 ms ϫ pulse-pulse interval, TE ϭ 15 ms, FOV ϭ 22, matrix ϭ 256 ϫ 144, slice thickness/ gap ϭ 5.0/0.5 mm, b-value ϭ 400 s/mm 2 ). ADC maps were calculated using the Philips vendor software on the MR imaging scanner console immediately after acquisition of DWI data. Mean and SD of ADC values within approximately 1-cm ROIs drawn within the lesions were determined independently by 2 board-certified radiologists. Each radiologist drew multiple ROIs for lesions that exceeded 3 cm and averaged the means within these ROIs, to avoid limited regional sampling of spatially heterogeneous lesions. Nonenhancing T2 hyperintense areas suspicious for cystic or necrotic areas were not included within any ROI. Volumes of masslike lesions were approximated by using the volume formula for an ellipsoid; volume ϭ (4/3) ϫ ϫ aϫ bϫ c, where a, b, and c were orthogonal linear dimensions of the lesion measured by one radiologist. (Volume measurements were not performed on infiltrative lesions that consisted of more subtle nerve thickening without a well-defined mass with a diameter at least 50% larger than that of the nerve of origin.)
Statistical Analysis
Intrarater reliability for ADC measurements was determined through calculation of the Pearson correlation coefficient be- tween separate measurements performed for each lesion by a single radiologist. Interrater reliability was determined through the Pearson correlation coefficient between measurements performed on each lesion by the 2 different radiologists.
One-way between-groups ANOVA was performed to assess for a statistically significant difference in ADC values among the 3 groups (benign lesions, malignant lesions, and postradiation changes) at P Ͻ .05. Post hoc pair-wise comparisons were then performed using the Tukey test to assess for statistically significant pair-wise differences between pairs of groups at P Ͻ .05.
Although ADC values within each group satisfied the ShapiroWilk test for normality, the sensitivity of this test for nonnormality may be reduced for small sample sizes. 17 The nonparametric Kruskal-Wallis test was also performed on the ADC values to assess for a statistically significant difference across groups at P Ͻ .05. Post hoc nonparametric pair-wise comparisons were performed using Mann-Whitney U tests to assess for statistically significant differences between pairs of groups at P Ͻ .05. All statistical analyses were performed using SPSS, Version 19 (IBM, Armonk, New York).
This study was approved by the institutional committee on human subjects research. All patient data stored for the purpose of this research study were anonymized by using accession numbers to identify each case.
RESULTS
The On-line Table shows diagnoses in 23 patients divided into 3 groups on the basis of biopsy results (n ϭ 10); long-term clinical and imaging follow-up (n ϭ 10; mean follow-up, 40 Ϯ 31 months); or intermediate-term follow-up supplemented by PET, neurologic examination, and/or nerve conduction studies (n ϭ 3, mean follow-up, 4 Ϯ 1 months). Group 1 (n ϭ 10) consisted of benign masses, including 4 biopsy-proven schwannomas, 1 biopsyproven neurofibroma, and 5 peripheral nerve masses that demonstrated both long-term stability in size and conventional MR imaging features characteristic of a benign primary nerve sheath tumor. Group 2 (n ϭ 7), malignant tumors, consisted of 1 biopsy-proven malignant peripheral nerve sheath tumor, 1 biopsyproven rhabdomyosarcoma, 2 cases of metastatic breast cancer involving the brachial plexus (biopsy-proven) or the sacral nerves, 1 case of biopsy-proven metastatic renal cell carcinoma involving a cervical nerve, 1 case of biopsy-proven non-Hodgkin lymphoma involving the sciatic nerve, and 1 case of acute lymphoblastic leukemia involving the brachial plexus. Group 3 (n ϭ 6) consisted of postradiation changes without evidence of residual tumor in 6 cases of previously irradiated malignancies, including 3 cases of breast cancer, 1 highgrade sarcoma, 1 case of Hodgkin lymphoma, and 1 case of oral squamous cell carcinoma. Lesion volumes ranged from 1 to 5530 cm 3 The nonparametric Kruskal-Wallis test also showed a statistically significant difference in ADC across the 3 groups, with 2 (df ϭ 2, 23 subjects) ϭ 15.0 and P ϭ .00056. Finally, post hoc nonparametric pair-wise comparisons using the Mann-Whitney U test showed a statistically significant difference in ADC between Groups 1 and 2 (P ϭ .00010) and between Groups 2 and 3 (P ϭ .0012), but no statistically significant difference between Groups 1 and 3 (P ϭ .97).
Figs 2-9 demonstrate MR images of representative cases from each of the 3 groups (benign lesions, malignant lesions, and postradiation changes).
DISCUSSION
Peripheral polyneuropathies affect multiple peripheral nerves and are generally caused by systemic diseases, most commonly diabetes, and vitamin deficiency related to alcohol use or pernicious anemia, in the United States and Europe. Polyneuropathies are usually diagnosed through clinical history, physical examination, laboratory studies, nerve conduction studies, and needle electromyography. 6, 18 Unlike polyneuropathies, mononeuropathies and plexopathies are most often due to trauma, nerve compression syndromes at characteristic anatomic locations, mass lesions, and postradiation changes; and imaging can play a decisive role in diagnosis. In a study of MR imaging of symptomatic nontraumatic brachial plexopathy, postradiation change was the most common cause, accounting for 31% of cases, with metastatic breast cancer and primary or metastatic lung cancer accounting for 24% and 19% of cases, respectively. The remaining 26% of cases were caused by a wide variety of benign and malignant tumors. 5 Unlike many cases of diffuse polyneuropathy, patients with brachial or lumbosacral plexopathy frequently undergo MR imaging due to the localized distribution of symptoms and presumed localized extent of the pathologic findings. 19, 20 We characterized the diffusivity of masslike or infiltrative lesions of the peripheral nerves discovered on MR imaging performed for a clinical indication of peripheral mononeuropathy or brachial or lumbosacral plexopathy. We demonstrated a statistically significant difference among the diffusivities of benign and malignant tumors and postradiation changes. This result is compatible with other studies that have demonstrated diffusivity to be generally inversely correlated with tumor cellularity and tumor grade in several contexts, including adult and pediatric brain tumors, head and neck masses, lymph nodes, retroperitoneal softtissue masses, [10] [11] [12] [13] [14] [15] [16] 21 and MR neurography. 9 Our results are also consistent with a prior study 9 in which a statistically significant difference in ADC values between benign (1.85 Ϯ 0.40 ϫ 10 Ϫ3 mm 2 /s) and malignant (0.90 Ϯ 0.25 ϫ 10 Ϫ3 mm 2 /s) peripheral nerve tumors and tumorlike masses was reported (P Ͻ .001). In the current study, we extended the analysis to include infiltrative postradiation changes of the peripheral nerves that were not included in that previous study. We report a complete separation of ADC values between benign and malignant lesions, with malignant lesions demonstrating ADC Յ 1.08 ϫ 10 Ϫ3 mm 2 /s, and benign lesions demonstrating ADC Ն 1.30 ϫ 10 Ϫ3 mm 2 /s.
The apparent diffusion coefficient is a measure of the diffusivity, or microscopic mobility, of water protons in tissue. The difference in ADC values of the lesions in our study was likely due to factors such as tumor cellularity, integrity of cell membranes, nuclear-to-cytoplasmic ratio, and the water content of the extracellular matrix. These have been postulated to account for low diffusivity within malignant solid tumors in prior studies. [10] [11] [12] [13] [14] [15] [16] 21 A study of benign and malignant extracranial soft-tissue tumors in children showed an inverse relationship between ADC measurements and cellular density derived from histologic analysis, but correlation was only moderate (R 2 ϭ 0.54), and it was postulated that additional factors such as extracellular water content also influence the ADC. 22 Myxoid matrix is known to be abundant in both schwannomas and neurofibromas. Schwannomas, particularly Antoni B tissue within schwannomas, contain a high water content, due to low cellularity and high mucin and low collagen content, 23 and this likely accounts for their high diffusivity. Limitations of this study include the lack of biopsy-proven diagnoses for all patients, the likelihood that diffusion characteristics of postradiation changes evolve with time, and the need for validation in a larger study population. Some malignant peripheral nerve sheath tumors, which may arise either de novo or from malignant degeneration of plexiform neurofibromas, have been shown to have a significant myxoid content; one prior study of soft-tissue masses reported that ADC failed to differentiate benign from malignant myxoid soft-tissue tumors, though only one malignant peripheral nerve sheath tumor was included in that study. 21 ADC values in postradiation change are likely to be affected by features such as edema, fibrous-inflammatory reaction, and vascular permeability that are temporally dynamic, particularly in the first few months after treatment. Long-term follow-up imaging rather than biopsy was more often performed for lesions with benign features on conventional imaging, introducing a bias, because biopsy was performed on all lesions that ultimately received a malignant diagnosis but on only a subset of lesions receiving a benign diagnosis. Finally, rare entities such as perineuroma 24 and posttraumatic neuroma appear as mass lesions of the peripheral nerves, but were not included within our study population.
CONCLUSIONS
We demonstrate a statistically significant difference in diffusivity between biopsy-proven malignant lesions, and lesions with either biopsy-proven benign histology or stable size and benign features on follow-up imaging. Although our results need to be validated in a larger study population, the pattern of diffusivity values within benign and malignant lesions described here may be helpful in selecting patients for percutaneous tissue sampling, debulking versus en bloc total resection, and/or short-term clinical and imaging follow-up.
